{"organizations": [], "uuid": "e962eb0ac8e28ebe165b61cc06d1f7937795415a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180425.html", "section_title": "Archive News &amp; Video for Wednesday, 25 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-galapagos-q1-operating-loss-widens/brief-galapagos-q1-operating-loss-widens-to-32-0-million-euros-idUSFWN1S21A6", "country": "US", "domain_rank": 408, "title": "BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T04:35:00.000+03:00", "replies_count": 0, "uuid": "e962eb0ac8e28ebe165b61cc06d1f7937795415a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-galapagos-q1-operating-loss-widens/brief-galapagos-q1-operating-loss-widens-to-32-0-million-euros-idUSFWN1S21A6", "ord_in_thread": 0, "title": "BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros", "locations": [], "entities": {"persons": [{"name": "finch", "sentiment": "none"}], "locations": [{"name": "isabela", "sentiment": "none"}, {"name": "co", "sentiment": "none"}], "organizations": [{"name": "galapagos nv", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "gilead", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - GALAPAGOS NV:\n* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO\n* Q1 OPERATING LOSS EUR 32.0 MILLION VERSUS LOSS OF EUR 11.2 MILLION YEAR AGO\n* Q1 NET LOSS FOR THE PERIOD EUR 37.3 MILLION VERSUS LOSS OF EUR 13.6 MILLION YEAR AGO\n* CASH AND CASH EQUIVALENT AT END-Q1 EUR 1.11 BILLION VERSUS EUR 0.95 BILLION YEAR AGO\n* AIMS TO REPORT TOPLINE RESULTS WITH FINCH 2 (RHEUMATOID ARTHRITIS) AND EQUATOR (PSORIATIC ARTHRITIS) IN 2018\n* AIMS TO REPORT TOPLINE RESULTS WITH TORTUGA (ANKYLOSING SPONDILITIS) FILGOTINIB STUDY IN 2018\n* IN 2018, AIMS TO REPORT DECISION TO CONTINUE TO PHASE 3 IN SELECTION (ULCERATIVE COLITIS)\n* IN 2018, COâ€™S PARTNER GILEAD TO COMPLETE RECRUITMENT OF REMAINING RA PHASE 3 STUDIES WITH FILGOTINIB\n* IN 2018, FOR CYSTIC FIBROSIS, EXPECTS READOUT OF PELICAN PATIENT STUDY WITH GLPG2737\n* IN 2018, FOR CYSTIC FIBROSIS, EXPECTS INTERIM READOUT WITH FIRST TRIPLE COMBINATION THERAPY IN FALCON\n* TO START DOSING ISABELA LATER IN 2018 * TO INITIATE PHASE 2 STUDIES WITH GLPG1205 (IPF), ADDITIONAL CF TRIPLE COMBINATION, GLPG1972 (OSTEOARTHRITIS), AND MOR106 (ATOPIC DERMATITIS) LATER IN 2018\n* EXPECTS OPERATIONAL CASH BURN BETWEEN EUR 220 MILLION AND EUR 240 MILLION IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-26T04:35:00.000+03:00", "crawled": "2018-04-26T20:49:36.002+03:00", "highlightTitle": ""}